- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02886234
Health Improvement Project - Providence (HIP)
Mindfulness Training to Improve ART Adherence and Reduce Risk Behavior Among Persons Living With HIV
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Two-thirds of people living with HIV show sub-optimal adherence to antiretroviral therapy (ART) and one-third engages in risky sex. Both non-adherence and risky sex have been associated with emotional distress and impulsivity. In this trial, the investigators will examine the utility of phone-delivered mindfulness training (MT) for people living with HIV. The primary outcomes comprise feasibility and acceptability of phone-delivery; secondary outcomes are estimates of efficacy of MT on adherence to ART and safer sexual practices as well as on their hypothesized antecedents.
Fifty participants will be enrolled in this parallel-group randomized clinical trial (RCT). Outpatients recruited from an HIV treatment clinic will be randomized (1:1 ratio) to either MT or to health coaching intervention; both interventions will be administered during 8 weekly phone calls. ART adherence (self-reported measure and unannounced phone pill counts), sexual behavior (self-reports and biomarkers), mindfulness, depression, stress, and impulsivity will be measured at baseline, post-intervention, and 3 months post-intervention.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02906
- The Miriam Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- HIV infection
- Sub-optimal adherence to ART (Less than "always" taking ART medication and/or viral load > 20 copies/mL);
- Psychological distress (PHQ-4 score ≥ 2);
- Recent risky sexual behavior (any unprotected sex OR > 1 sexual partner over the past 6 months)
- Access to a telephone or cell phone
Exclusion Criteria:
- Unwilling or unable to provide informed consent
- Cognitive impairment
- Non-English speaking
- Low literacy (i.e., reporting they "often" or "always" need someone to read instructions, pamphlets, or other written material from a doctor or pharmacy to them
- Enrolled in another behavioral trials
- Prior formal mindfulness training or have practiced of mindfulness or related mind-body techniques in the previous year
- Severe hearing impairment not allowing phone delivery
- Suicidal ideation
- Planning to move out of the area within the study period
- Clinic provider advising against recruitment in the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Mindfulness training (MT)
Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
|
Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks.
).
In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
|
Comparateur actif: Health Coaching (HC)
Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
|
The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition.
To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Feasibility of Intervention
Délai: post-intervention, 9 to 10 weeks after baseline
|
Feasibility - as indicated by the number of patients attending at least 50% of sessions
|
post-intervention, 9 to 10 weeks after baseline
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Acceptability of the Intervention
Délai: post-intervention, 9 to 10 weeks after baseline
|
Number of patients reporting "very satisfied" or "mostly satisfied" with their intervention
|
post-intervention, 9 to 10 weeks after baseline
|
Antiretroviral Medication Adherence
Délai: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Self-reported number of missed days of medication
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Self-reported Sexual Risk Behavior
Délai: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Self-reported risky sexual behavior as indicated by the percentage of episodes of condom protected sexual intercourse Higher values are better outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Five Facet Mindfulness Questionnaire
Délai: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Five Facet of Mindfulness Questionnaire (15 items; short form) Construct = Mindfulness Minimum total scale score = 15 Maximum total scale score = 75 Scoring: sum across all 15 items Higher scores represent a better outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Perceived Stress Scale
Délai: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Perceived Stress Scale (4-item version) Construct = perceived stress Minimum total scale score = 0 Maximum total scale score = 16 Scoring: reverse score items 2 and 3, then sum across all 4 items Higher scores represent a worse outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Barratt Impulsiveness Scale
Délai: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Barratt Impulsiveness Scale (short form, 8 items) Construct = Impulsivity Minimum total scale score = 8 Maximum total scale score = 32 Scoring: reverse score items 1, 4, 5, 6, and then sum across all 8 items Higher scores represent a worse outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Patient Health Questionnaire
Délai: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Patient Health Questionnaire (9 item version) Construct measured = depression Minimum total scale score = 0 Maximum total scale score = 27 Scoring: sum across all 9 items Higher scores represent a worse outcome
|
Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: MIchael P Carey, PhD, Centers for Behavioral and Preventive Medicine, The Miriam Hospital
- Chercheur principal: Elena Salmoirago-Blotcher, MD, PhD, Centers for Behavioral and Preventive Medicine, The Miriam Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- R34AT008930 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur VIH
-
Icahn School of Medicine at Mount SinaiIRRASRecrutementHémorragie intraventriculaire (HIV)États-Unis
-
Yale UniversityComplétéPrématurité | Nourrissons de très faible poids à la naissance | Hémorragie intraventriculaire (HIV) | Saignement dans le cerveauÉtats-Unis
Essais cliniques sur Mindfulness Training (MT)
-
Università degli Studi di SassariComplétéSclérose en plaques | Fatigue | FaiblesseItalie
-
Universidad Complutense de MadridComplété
-
Mitsubishi Tanabe Pharma CorporationComplétéNéphropathie diabétiqueJapon
-
Mitsubishi Tanabe Pharma America Inc.ComplétéBouffées de chaleur de la ménopauseÉtats-Unis
-
Mitsubishi Tanabe Pharma America Inc.RésiliéEn bonne santéRoyaume-Uni
-
Renrong WuComplété
-
Mitsubishi Tanabe Pharma CorporationComplétéSclérose en plaques récurrente-rémittenteCroatie, Bulgarie, République tchèque, Italie, Fédération Russe, Espagne, Royaume-Uni, Allemagne, Lituanie, Pologne, Belgique, Hongrie, Serbie, Finlande, Ukraine, Suisse, Canada, Turquie
-
Mitsubishi Tanabe Pharma CorporationComplétéPsoriasis en plaquesBulgarie, Fédération Russe, Estonie, Hongrie, Lettonie, Pologne, Ukraine, Allemagne
-
Mitsubishi Tanabe Pharma CorporationComplétéSclérose en plaques récurrente-rémittenteBelgique, Bulgarie, Canada, Croatie, République tchèque, Finlande, Allemagne, Hongrie, Italie, Lituanie, Pologne, Fédération Russe, Serbie, Espagne, Turquie, Ukraine, Royaume-Uni
-
Queen's UniversityComplétéLes troubles mentauxCanada